EN | SE Contact us

Technology platforms


The Company’s technology platforms consist of the n-CoDeR® antibody library and the unique F.I.R.S.T.™ development tool. From n-CoDeR®, a library developed by BioInvent containing fully human antibodies, drug candidates that bind specifically and firmly to their target structures can be identified. With the help of the unique, function-based F.I.R.S.T.™ platform, where patient material is the foundation throughout the development process, the most clinically relevant target structures in a disease model and matching antibodies can be identified simultaneously.



F.I.R.S.T.™ - a tool for effective drug development

BioInvent has developed a patented screening tool called F.I.R.S.T.™, which is an important technical tool for internal drug development as well as for external development partners. The platform facilitates the development of new antibody therapies, as new drug candidates can be produced without detailed knowledge of the antibodies’ target proteins. This unique method has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.




The method makes it possible to simultaneously investigate antibody binding to both diseased and healthy tissue in order to select those antibodies and target structures that are unique for diseased tissue in terms of binding and expression. Through functional, high-capacity screening, antibodies are then selected based on their ability to, for example, induce cell death of primary cancer cells or improve the immune system’s capacity to eliminate tumour cells.




n-CoDeR® - antibody library

BioInvent’s antibody library contains more than 30 billion human antibody genes stored within bacteria in test tubes. The bacteria act as production units for various antibodies, making it possible to search the library to identify precisely those antibodies that bind to a specific target protein. The n-CoDeR® library is searched using an established technology called phage display. To identify an optimal antibody, BioInvent has developed automated processes in which robots carry out the analysis on an industrial scale. The n-CoDeR® library consists of naturally occurring antibody genes. Every component comes from nature, but the combinations are largely new, making it possible to build an antibody repertoire that is greater than nature’s own variability. BioInvent calls this “evolution beyond nature.” The n-CoDeR® library is protected by patents in the most important markets.

 Intellectual property


Patent protection is an important component of all projects. BioInvent owns and has licenses to a global patent portfolio relating to its product pipeline, including different antibodies and therapeutic uses thereof, and to the n-CoDeR® and F.I.R.S.T.™ technology platforms. Know-how concerning products and technologies constitutes another important intellectual property asset of BioInvent. BioInvent further owns selected trademarks.

Scientific Publications

Roghanian A, Teige I, Mårtensson L, Cox K, Kovacek M, Ljungars A, Mattsson J,Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan CHT, Li ZL, Williams E, Manfredi G,Oldham RJ, Mockridge IC,James SA, Dahal LN, Hussain K,Nilsson B,Verbeek SJ, Juliusson G, Hansson M, Jerkeman M,Johnson PWM,Davies A, Beers SA,Glennie MJ,Frendéus B, Cragg MS. Antagonistic Human FcgRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. Cancer Cell. 2015, April 13, 27:473–488

Hansson M, Gimsing P, Badros AZ, Martinsson-Niskanen T, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M and Tricot G. A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma. Clinical Cancer Research. 2015 Febr 24, 2015 10.1158/1078-0432.CCR-14-1661

Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, Chowdhury F, Frendéus B, Harper KS, Strefford JC, Cragg MS, Glennie MJ, Williams AP, French RR. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125(1):102-10

Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, Rudd JH, Hsieh F, Ballantyne CM, Ghoshhajra B, Rosenson RS, Koren M, Roth EM, Duprez DA, Fayad ZA, Tawakol AA. A Phase II Study of the Safety, Tolerability, and Anti-Inflammatory Activity as Assessed by FDG-PET of MLDL1278A, a Monoclonal Antibody Against Oxidized LDL, in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease. JACC Cardiovasc Imaging. 2014 Nov 12. pii: S1936-878X(14)00780-3

Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, Shah V, Roghanian A, Frendéus B, Glennie MJ, Cragg MS. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood. 2014 Jan 30;123(5):669-77

Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, Valfridsson C, Bullens S, Messaoudi I, Bader L, Cowan KJ, Kamath A, van Bruggen N, Bunting S, Frendéus B, Grove KL. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab. 2013 Jun 11;2(3):256-69

Frendéus B. Function-first antibody discovery: Embracing the unpredictable biology of antibodies. Oncoimmunology. 2013 Aug 1;2(8):e25047. Epub. 2013 May 20

Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, Li Z, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, Mårtensson L, Teige I, Tricot G, Frendéus B. A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo. Cancer Cell. 2013 Apr 15;23(4):502-15

Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010 Jun;32(6):1205-20.

Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-75.

Fransson J, Tornberg UC, Borrebaeck CA, Carlsson R, Frendéus B. Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies. Int J Cancer. 2006;119(2):349-58. 

Schiopu A, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MP, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation. 2004;110(14):2047-52.

Schiopu A, Frendéus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol. 2007;50(24):2313-8. 

Söderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, Nilsson A, Jansson B, Ohlin M, Wingren C, Danielsson L, Carlsson R, Borrebaeck CA. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol. 2000;18(8):852-6. 

Ström A, Fredrikson GN, Schiopu A, Ljungcrantz I, Söderberg I, Jansson B, Carlsson R, Hultgårdh-Nilsson A, Nilsson J. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis. 2007;190(2):298-305.